Founded in 2021, Veritas Medicine brings AI, natural-product science and experimental research together. Two complementary engines—custom R&D and original drug incubation—advance innovation for global development.
Company profile
Veritas Medicine (Shanghai) Co., Ltd., founded in 2021, is a biopharmaceutical company advancing innovation in natural medicines through artificial intelligence. Its three research directions are natural-origin original molecules, global botanical drugs and innovative traditional Chinese medicine (TCM) drugs. The company’s proprietary VMED-OS TCM AI model integrates knowledge graphs and clinical data, combining computational prediction with experimental validation to support drug discovery and development for unmet clinical needs.
Veritas combines original drug incubation with custom R&D. Its capabilities span active constituent discovery, intelligent formulation, pharmacological evaluation, drug substance and formulation development, and quality standards research, supporting the translation of scientific discoveries into drug candidates and clinical research. The company has assembled a technical team for international botanical drug development and traditional Chinese medicine development, with members from leading institutions in China and abroad, including Harvard University in the United States, Okayama University in Japan, Shanghai Jiao Tong University, the Chinese Academy of Sciences, Shanghai University of Traditional Chinese Medicine and Beijing University of Chinese Medicine.
Veritas advances the heritage and innovation of Chinese medicine by integrating the core principles of TCM theory with modern pharmaceutical technologies. The company collaborates with leading TCM experts in China and scientist teams worldwide, and works with leading tertiary hospitals to advance hospital-preparation translation and investigator-initiated trials (IITs). Guided by contemporary clinical needs, its approach uses AI-assisted modern science to explain the efficacy and mechanisms of Chinese medicines, translating traditional experience into quantifiable, verifiable and reusable data assets.
Our vision
To be a global leader inAI-driven innovation in natural medicines
Bringing nature-inspired medicines to patients worldwide.
Grounded in the wisdom of Chinese medicine and modern science, we aspire to work with partners worldwide to expand treatment possibilities and create lasting value for human health.
The Veritas ethos
Balance sustains us. Truth moves us forward.
Junheng · A heritage of Chinese medicine
01
Rooted in balance
Junheng echoes the Chinese word for balance, reflecting a view of life that connects people with nature and understands the body as an integrated whole. Harmony and balance guide our exploration of Chinese medicine’s contribution to health.
02
Jun: an ambition to lead
In traditional formula design, Jun denotes the principal herb within a coordinated combination. It expresses our ambition to lead innovation in Chinese medicine, bringing traditional wisdom and modern science together to explore new possibilities in natural medicines.
03
Heng: an enduring commitment
Heng signifies continuity and lasting vitality. We carry forward the accumulated wisdom of Chinese medicine with patience and integrity, advancing its heritage through sustained inquiry and innovation.
Veritas · The pursuit of truth
Latin for truth, Veritas expresses our commitment to testable pharmacology, explainable mechanisms and measurable quality.
The meaning of our mark
A capsule gives the mark its form; a pulse gives it life. The blue-green identity brings nature and technology together. Chinese medicine informs our purpose; modern science provides the means to explore it.
Key milestones
2021
Founded in Shanghai
Veritas Medicine begins its journey in natural medicines and TCM innovation.
2023
Building development capabilities
The parent company, Hangzhou Junheng, is established with angel financing exclusively from Huafang Capital, expanding development and custom research capabilities.
2024
Helping a partner advance
Helped our first client obtain clinical-trial authorization for an innovative drug, connecting CMC, preclinical research and regulatory work.
2025
VMED-OS launches
The TCM AI model connects knowledge graphs and clinical data, integrating computational research with wet-lab experiments to advance original programs and custom R&D.
2026
AI-powered formulation for innovative drug R&D
AI-driven development of innovative TCM drugs, botanical drugs and original medicines from natural sources.
2026
CMA qualification and CNAS accreditation
Granted qualifications for quality testing of Chinese medicinal materials and Chinese patent medicines.
2026
Our own national-level research platform
Approved as the “Key Laboratory for Quality & Safety Monitoring of Jiangxi TCM, MARA”.